Deaths associated with inappropriate intravenous colchicine administration

Intravenous (IV) colchicine is occasionally prescribed for the treatment of acute gouty arthritis. The Food and Drug Administration (FDA) recently received a report of death in a patient that was associated with inappropriate IV dosing of colchicine. This report prompted further investigation of oth...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of emergency medicine 2002-05, Vol.22 (4), p.385-387
Main Authors: Bonnel, Renan A, Villalba, Maria L, Karwoski, Claudia B, Beitz, Julie
Format: Article
Language:English
Subjects:
Acute Disease
Aged
Aged, 80 and over
Biological and medical sciences
colchicine
Colchicine - administration & dosage
Colchicine - poisoning
Colchicine - therapeutic use
Drug Overdose
Drug toxicity and drugs side effects treatment
Fatal Outcome
gout
Gout - drug therapy
Gout Suppressants - administration & dosage
Gout Suppressants - poisoning
Gout Suppressants - therapeutic use
Humans
Injections, Intravenous
intravenous
Male
Medical sciences
Miscellaneous (drug allergy, mutagens, teratogens...)
Pharmacology. Drug treatments
Practice Guidelines as Topic
United States
United States Food and Drug Administration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intravenous (IV) colchicine is occasionally prescribed for the treatment of acute gouty arthritis. The Food and Drug Administration (FDA) recently received a report of death in a patient that was associated with inappropriate IV dosing of colchicine. This report prompted further investigation of other deaths associated with IV colchicine use in the FDA Adverse Event Reporting System (AERS) and the medical literature. A total of 20 deaths were identified. Eight patients were females, 11 were males, and the gender was unknown in 1. In all cases, the recommended maximum cumulative dose of 2 to 4 mg during a course of therapy was exceeded. Dose reductions are recommended in patients with renal or hepatic disease and in the elderly. All reported adverse events were associated with colchicine toxicity, including thrombocytopenia, leukopenia, pancytopenia, agranulocytosis, aplastic anemia, acute renal failure, and disseminated intravascular coagulopathy. Death occurred within 1 to 40 days after drug administration. Therapeutic guidelines exist for use of IV colchicine and these guidelines should be followed to prevent serious toxicities and death.
ISSN:0736-4679
2352-5029
DOI:10.1016/S0736-4679(02)00430-4